SI-BONE (SIBN) Competitors

TransMedics Group (NASDAQ:TMDX) and SI-BONE (NASDAQ:SIBN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.

Does the media favor TMDX or SIBN?

In the previous week, TransMedics Group had 44 more articles in the media than SI-BONE. MarketBeat recorded 47 mentions for TransMedics Group and 3 mentions for SI-BONE. SI-BONE's average media sentiment score of 1.81 beat TransMedics Group's score of 0.18 indicating that SI-BONE is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	8 Very Positive mention(s)	8 Positive mention(s)	26 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
SI-BONE	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, TMDX or SIBN?

TransMedics Group has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.

Do analysts rate TMDX or SIBN?

TransMedics Group presently has a consensus price target of $122.70, indicating a potential upside of 81.32%. SI-BONE has a consensus price target of $24.40, indicating a potential upside of 81.14%. Given TransMedics Group's higher probable upside, analysts clearly believe TransMedics Group is more favorable than SI-BONE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
SI-BONE	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer TMDX or SIBN?

SI-BONE received 60 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 68.80% of users gave SI-BONE an outperform vote while only 58.95% of users gave TransMedics Group an outperform vote.

Company	Underperform	Outperform
TransMedics Group	Outperform Votes 112 58.95%	Underperform Votes 78 41.05%
SI-BONE	Outperform Votes 172 68.80%	Underperform Votes 78 31.20%

Which has better valuation & earnings, TMDX or SIBN?

TransMedics Group has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$441.54M	5.16	-$25.03M	$1.01	67.00
SI-BONE	$167.18M	3.42	-$43.34M	-$0.76	-17.72

Do insiders & institutionals believe in TMDX or SIBN?

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 98.1% of SI-BONE shares are held by institutional investors. 7.0% of TransMedics Group shares are held by company insiders. Comparatively, 3.9% of SI-BONE shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is TMDX or SIBN more profitable?

TransMedics Group has a net margin of 8.14% compared to SI-BONE's net margin of -23.82%. TransMedics Group's return on equity of 18.74% beat SI-BONE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	8.14%	18.74%	4.39%
SI-BONE	-23.82%	-22.51%	-16.53%

Summary

TransMedics Group beats SI-BONE on 15 of the 19 factors compared between the two stocks.